Biogen paid $5.6B for Apellis, and a new SEC filing confirmed the deal details CEO Chris Viehbacher has been engineering: a company that doesn’t grow on neurology alone.
That’s the logic behind the price: commercial revenue outside neurology, and a platform that can expand to additional complement-driven indications.
Viehbacher has been steering Biogen toward diversification since becoming CEO. The high-risk neurology bets that defined the company’s legacy are the reason. This $5.6B deal is the most concrete step in that direction.
The deal terms came through the regulatory filing, not a press release. Read the filing if you want the fine print.
Elsewhere, Telix Pharmaceuticals also raised $600M in a round announced Wednesday. Obsidian also announced plans to go public.
For Biogen shareholders, the question is what $5.6B in complement actually delivers. Whether it can grow fast enough to offset pressure on the legacy portfolio is Viehbacher’s call now.
— Diana Kowalski